Canadians relying on public insurance plans face significant delays accessing new medicines. This graph breaks down the sequential approval and listing process, and demonstrates how long it takes Canadians to access innovative medicines.
Our resource hub to discover reports, policy papers and other forms of informative content
Statistic’s Canada outlines the economic impact of the Canadian research and development pharmaceutical sector.
How Would a Single-Payer Publicly Funded National Pharmacare Program Affect the Quality of Access to Medicines for Canadian Patients?
Canada’s dual-payer pharmacare program works for most Canadians. But gaps need to be filled to ensure all Canadians have access to the medicines they need, regardless of income, age, sex or postal code.
The PMPRB proposed a sweeping, controversial reform of its patented medicine prices oversight regime. This infographic outlines therapeutic areas likely to be impacted, and the percentage of timely new drug submission within 12 months of the first global submission.
Canada and other OECD20 countries launch a similar number of innovative medicines. However, our public plans reimburse 32 to 45 per cent less.
Time to Listing: Canada’s public plans cover fewer new medicines and take longer than most OECD countries to approve them
Public plans in Canada cover fewer medicines than in other OECD20 countries and take longer to be approved. For rare-disease medicines, this gap is even larger.
Time to Listing: Canada’s drug review and public reimbursement process is sequential and every step adds to the timeline
Wait times to reimburse life-saving medications are getting longer as the sequential process of reviews causes delays for patients.